中性粒细胞/淋巴细胞比值在接受膀胱内吉西他滨/多西他赛治疗的高危BCG初治非肌层浸润性膀胱癌中的预后作用
本研究回顾性分析2011年1月至2021年12月接受膀胱内序贯吉西他滨/多西他赛(Gem/Doce)治疗的115例高危BCG初治非肌层浸润性膀胱癌患者,评估治疗前中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)对疗效的预测作用。中位随访23个月,NLR与无复发生发生存(RFS)相关(HR 1.32,95%CI 1.19-1.46),C指数0.7(P<0.01);PLR和血小板计数与RFS无关,上述炎症标志物对总生存均无预测价值。
要点
- 治疗前NLR与接受Gem/Doce的高危BCG初治NMIBC患者的RFS相关,HR 1.32(95%CI 1.19-1.46)。
- NLR预测RFS的C指数为0.7(P<0.01)。
- PLR和血小板计数与RFS无关,所有标志物对总生存均无预测价值。
核心结论
- 治疗前NLR对接受Gem/Doce的高危BCG初治NMIBC患者的RFS提供一定预测准确性。
- 作者指出需进一步开展前瞻性试验验证该发现。
研究设计与样本
- 回顾性分析2011年1月至2021年12月接受膀胱内Gem/Doce治疗的115例高危BCG初治NMIBC患者。
- 采用Cox回归分析判断治疗前中性粒细胞增多、NLR、血小板计数和PLR对RFS和OS的预测作用,并用Uno C统计量评估预测效能。
主要发现
- 总体队列中位随访23个月(IQR 13-36)。
- NLR、PLR和血小板计数的均值(标准差)分别为3.4(2.3)、142.2(85.5)和225.2(75.1)×10⁹/L。
- NLR与RFS相关,HR 1.32(95%CI 1.19-1.46);一致性分析显示NLR对RFS预测能力良好(C指数0.7,P<0.01)。
- PLR和血小板计数与RFS无关,未预测复发;上述细胞炎症标志物对OS均无预测价值。
关键数值与推荐
- NLR与RFS相关:HR 1.32(95%CI 1.19-1.46)。
- NLR预测RFS的C指数为0.7(P<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文报告为回顾性分析。
- 作者指出需进一步前瞻性试验验证该发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the prediction of response to sequential intravesical therapy, gemcitabine and docetaxel (Gem/Doce), given to patients with bacille Calmette-Guérin (BCG)- naïve high-risk non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: A retrospective analysis was conducted on 115 patients who received intravesical Gem/Doce for high-risk NMIBC between January 2011 and December 2021. Data were computed as the median (interquartile range [IQR]) or mean (standard deviation [sd]). Cox regression analysis was performed to determine if neutrophilia, NLR, platelet counts, and PLR before instillation therapy were predictive of recurrence-free survival (RFS) and overall survival (OS). Predictive performance was estimated using Uno's C-statistic. RESULTS: The median (IQR) follow-up for the overall cohort was 23 (13-36) months. The mean (sd) values for NLR, PLR and platelet counts were 3.4 (2.3), 142.2 (85.5), and 225.2 (75.1) × 109/L, respectively. NLR was associated with RFS, with a hazard ratio of 1.32 (95% confidence interval CI 1.19-1.46). Concordance analysis showed that NLR had a good ability to predict RFS (C-index: 0.7, P < 0.01). The PLR and platelet count were not associated with RFS and did not predict recurrence. In terms of OS, none of these cellular inflammatory markers showed any prediction value. CONCLUSION: Pre-treatment NLR provides some predictive accuracy for RFS in high-risk BCG-naïve patients receiving Gem/Doce. Further prospective trials are needed to validate this finding.
引用
- Chakra MA, Lassila R, El Beayni N, et al. Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel. BJU Int. 2024. PMID: 39082304. doi:10.1111/bju.16486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。